Condition
Refractory B Acute Lymphoblastic Leukemia clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Refractory B Acute Lymphoblastic Leukemia clinical trials that are recruiting, at sites in 2 countries (most in United States (5), Puerto Rico (1)). By phase: Phase 1 (3), Phase 1/2 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 2Countries
Newest Refractory B Acute Lymphoblastic Leukemia clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Pomalidomide after CAR T-cell therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma | Phase 1 | Ann Arbor, Michigan | Recruiting | Apr 16, 2026 |
| Erwinia asparaginase and venetoclax added to blinatumomab for relapsed/refractory CD19+ B‑ALL | Phase 1 | Duarte, California | Recruiting | Aug 21, 2025 |
| Genetically engineered CAR T-cells for treating certain blood cancers | Phase 1 | Columbus, Ohio and 1 other locations | Recruiting | Jun 14, 2022 |
| Inotuzumab ozogamicin and blinatumomab with optional ponatinib for CD22-positive B-cell acute lymphoblastic leukemia | Phase 2 | Birmingham, Alabama and 284 other locations | Recruiting | Nov 14, 2018 |
| Using inotuzumab ozogamicin with chemotherapy to treat acute lymphoblastic leukemia | Phase 1/2 | Houston, Texas | Recruiting | Jun 13, 2011 |
All recruiting trials (5)
-
Pomalidomide after CAR T-cell therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma
This phase 1 study tests whether pomalidomide, given after CD19 CAR T-cell therapy, is safe and may help people whose CD19+ B-cell leukemia or lymphoma has come back or not responded.
-
Erwinia asparaginase and venetoclax added to blinatumomab for relapsed/refractory CD19+ B‑ALL
This will test whether adding recombinant Erwinia asparaginase and venetoclax to blinatumomab helps adolescents and adults (12–55) with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia.
-
Genetically engineered CAR T-cells for treating certain blood cancers
This study is testing a new type of treatment using specially modified immune cells to see if they can help people with certain blood cancers that haven't responded to other treatments.
-
Inotuzumab ozogamicin and blinatumomab with optional ponatinib for CD22-positive B-cell acute lymphoblastic leukemia
This trial will test whether inotuzumab ozogamicin followed by blinatumomab, with or without ponatinib, can help people with CD22-positive B-cell acute lymphoblastic leukemia who are newly diagnosed, have relapsed, or are refractory to prior therapy.
-
Using inotuzumab ozogamicin with chemotherapy to treat acute lymphoblastic leukemia
This study is testing if a new drug combined with lighter chemotherapy can help older patients with acute lymphoblastic leukemia who can't handle stronger treatments.
Related topics
Quick answers
How many Refractory B Acute Lymphoblastic Leukemia clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (5 trials), Puerto Rico (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 3, Phase 1/2: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.